Literature DB >> 2301830

Effect of muramyl dipeptide on immunogenicity of Corynebacterium pseudotuberculosis whole-cell vaccines in mice and lambs.

K A Brogden1, L Chedid, R C Cutlip, H D Lehmkuhl, J Sacks.   

Abstract

Colostrum-deprived lambs and CF1 mice were vaccinated with water-in-oil emulsion vaccines containing nonviable whole cells (WC) of Corynebacterium pseudotuberculosis with and without muramyl dipeptide (MDP). Efficacy of vaccines was determined from the survival of mice and lesions in lambs after IV injection of 10(4) colony-forming units of C pseudotuberculosis. In mice, protection was related to the concentration of WC in the vaccine. At 50, 100, or 150 micrograms of WC, protection was good (78.8%). At 10 or 25 micrograms of WC, protection was considerably less (54.7%). At high WC concentrations, protection could only be moderately increased to 82.3% with high (50 and 100 micrograms) concentrations of MDP or increased to 90% protection with low (5 and 10 micrograms) concentrations of MDP. At low WC concentrations, protection significantly decreased to 32% (P less than 0.025) with high concentrations of MDP, but significantly increased to 72.5% (P less than 0.025) with low concentrations of MDP. Therefore, the amount of protection with lower concentrations of WC and MDP was comparable with the amount of protection with higher concentrations of WC without MDP. In lambs, high prechallenge antibody titers (geometric mean titers from 5.1 to 5.4 by day 35) were observed after vaccination with WC. Protection and vaccination site abscesses in lambs were related to the concentration of WC and MDP. Pulmonary or vaccination site abscesses were not observed in 4 of 4 lambs vaccinated with 1 mg of WC + 50 micrograms of MDP.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2301830

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  The incidence of caseous lymphadenitis in Alberta sheep and assessment of impact by vaccination with commercial and experimental vaccines.

Authors:  K Stanford; K A Brogden; L A McClelland; G C Kozub; F Audibert
Journal:  Can J Vet Res       Date:  1998-01       Impact factor: 1.310

2.  Identification of a novel antigen from Corynebacterium pseudotuberculosis that protects sheep against caseous lymphadenitis.

Authors:  J Walker; H J Jackson; D G Eggleton; E N Meeusen; M J Wilson; M R Brandon
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

3.  A field trial to evaluate a whole cell vaccine for the prevention of caseous lymphadenitis in sheep and goat flocks.

Authors:  P I Menzies; C A Muckle; K A Brogden; L Robinson
Journal:  Can J Vet Res       Date:  1991-10       Impact factor: 1.310

Review 4.  The circulating transcriptome as a source of non-invasive cancer biomarkers: concepts and controversies of non-coding and coding RNA in body fluids.

Authors:  Marta Fernandez-Mercado; Lorea Manterola; Erika Larrea; Ibai Goicoechea; María Arestin; María Armesto; David Otaegui; Charles H Lawrie
Journal:  J Cell Mol Med       Date:  2015-06-27       Impact factor: 5.310

5.  Vaccination against Corynebacterium pseudotuberculosis infections controlling caseous lymphadenitis (CLA) and oedematousskin disease.

Authors:  Ihab M Moussa; Mohamed S Ali; Ashgan M Hessain; Saleh A Kabli; Hassan A Hemeg; Salha Abdelkareem Selim
Journal:  Saudi J Biol Sci       Date:  2016-06-17       Impact factor: 4.219

Review 6.  Vaccines for caseous lymphadenitis: up-to-date and forward-looking strategies.

Authors:  Rodrigo Barros de Pinho; Mara Thais de Oliveira Silva; Francisco Silvestre Brilhante Bezerra; Sibele Borsuk
Journal:  Appl Microbiol Biotechnol       Date:  2021-03-02       Impact factor: 4.813

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.